Pallas Capital Advisors LLC Has $1.05 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Pallas Capital Advisors LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 19.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,673 shares of the company’s stock after buying an additional 1,225 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Neurocrine Biosciences were worth $1,047,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in NBIX. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $28,000. Blue Trust Inc. grew its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares in the last quarter. Plato Investment Management Ltd grew its holdings in shares of Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after buying an additional 130 shares in the last quarter. Truvestments Capital LLC acquired a new position in Neurocrine Biosciences during the third quarter valued at $63,000. Finally, True Wealth Design LLC lifted its stake in Neurocrine Biosciences by 11,740.0% in the 3rd quarter. True Wealth Design LLC now owns 592 shares of the company’s stock worth $68,000 after acquiring an additional 587 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,694 shares of company stock worth $479,230. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $143.03 on Tuesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The firm has a fifty day moving average price of $130.43 and a two-hundred day moving average price of $131.01. The firm has a market cap of $14.48 billion, a price-to-earnings ratio of 38.35 and a beta of 0.33.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NBIX. UBS Group lifted their target price on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Raymond James reissued an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, Barclays increased their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $164.81.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.